##Normal2 ref_correl: 0.944 (median: 0.9575)
##Normal2 cnvs: 21 (median: 4)
##Normal2 qc_errors: 
##DESCRIPTION=CGI_drug_assoc=Cancer Genome Interpreter - therapeutic biomarkers
##DESCRIPTION=CGI_evid_level=Cancer Genome Interpreter - evidence level
#chr	start	end	sample	size	region_count	region_copy_numbers	region_zscores	region_cnv_af	region_coordinates	overlaps_cnp_region	genes	dosage_sensitive_disease_genes	omim	CGI_drug_assoc	CGI_evid_level
chr1	97981256	97981522	Normal2	267	1	1	-3.55	0.039	chr1:97981256-97981522		DPYD	DPYD	612779_[DPYD_(CONFIRMED)_DIHYDROPYRIMIDINE_DEHYDROGENASE_DEFICIENCY,274270|5-FLUOROURACIL_TOXICITY,274270]	DPYD	FDA guidelines, CPIC guidelines
chr2	141259230	141260697	Normal2	1468	2	1,1	-3.55,-2.93	0.066,0.066	chr2:141259230-141259468,chr2:141260506-141260697		LRP1B			LRP1B	Early trials
chr9	75567825	75567983	Normal2	159	1	1	-3.98	0.039	chr9:75567825-75567983		ALDH1A1				
chr10	104860776	104861108	Normal2	333	2	3,3	2.55,3.65	0.026,0.118	chr10:104860776-104860884,chr10:104860966-104861108		NT5C2		600417_[NT5C2_(PROVISIONAL)_SPASTIC_PARAPLEGIA_45,AUTOSOMAL_RECESSIVE,613162]		
